Objective The purpose of this study was to investigate the effect of disease modifying
therapies on immune response to severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2…

Objective: The objective of this paper is to investigate demographic and disease factors
associated with changes in employment role and status in multiple sclerosis (MS). Methods: …

Background Age of onset of multiple sclerosis (MS) peaks in the 3rd and 4th decades and is
rarely less than 18. Robust longitudinal studies in paediatric-onset MS (POMS) are limited, …

OBJECTIVE: The expression of clinically significant depression symptoms during and post
multiple sclerosis (MS) relapse was investigated. The point prevalence of possible …

… Harding received funding for this project from the MS Society of Canada and has previously
received research support from Novartis UK for an unrelated project. M. Wardle reports no …

Background A minority of patients with multiple sclerosis (MS) have primary progressive
disease (PPMS). Treatment options are currently limited, but as prospects for interventional …

Background People with MS treated with anti-CD20 therapies and fingolimod often have
attenuated responses to initial COVID-19 vaccination. However, uncertainties remain about the …

The complement pathway has potential contributions to both white (WM) and grey matter (GM)
pathology in Multiple Sclerosis (MS). A quantitative assessment of complement …

The article discusses impact of the 2017 revisions to McDonald criteria on the diagnosis of
multiple sclerosis. It mentions that revisions to diagnostic criteria for multiple sclerosis (MS) in …

Objective Currently, 233 genetic loci are known to be associated with susceptibility to
multiple sclerosis (MS). Two independent pivotal severity genome‐wide association studies …